Our Therapies

OMISIRGE^® (Omidubicel onlv)

OMISIRGE^® is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord blood indicated for:

• use in adults and pediatric patients 12 years and older with hematologic malignancies following myeloablative conditioning.
• use in adults and pediatric patients with severe aplastic anemia following reduced intensity conditioning.

Full Prescribing Information,
including Boxed Warning

Learn more

APHEXDA^® (motixafortide)

APHEXDA^® is indicated in combination with filgrastim^† to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

^†Commonly referred to as granulocyte colony-stimulating factor (G-CSF).

Full Prescribing Information

Learn more

Gamida Cell Assist^®

Gamida Cell Assist^® (GCA) provides personalized support through every step of the Omisirge journey. GCA case managers can assist with patient enrollment, placing a cell order and tracking that order through manufacturing and delivery. They can also provide support with a wide range of reimbursement, financial and logistical services for transplant centers, eligible patients and caregivers.

Visit GamidaCellAssist.com for more information, including eligibility requirements.